The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Abstract
OBJECTIVE: To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer. RESEARCH DESIGN AND METHODS: A nested case-control analysis was performed with use of the French national health care insurance system (SNDS) database. Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006 and 2018 were included in the cohort. All thyroid cancers were identified through hospital discharge diagnoses and medical procedures between 2014 and 2018. Exposure to GLP-1 RA was measured within the 6 years preceding a 6-month lag-time period and considered as current use and cumulative duration of use based on defined daily dose (≤1, 1 to 3, >3 years). Case subjects were matched with up to 20 control subjects on age, sex, and length of diabetes with the risk-set sampling procedure. Risk of thyroid cancer related to use of GLP-1 RA was estimated with a conditional logistic regression with adjustment for goiter, hypothyroidism, hyperthyroidism, other antidiabetes drugs, and social deprivation index. RESULTS: A total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Use of GLP-1 RA for 1-3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04-3.05). CONCLUSIONS: In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concerns regarding the validity of outcomes have emerged, particularly owing to the reliance on indirect indicators such as the calcitonin test, carcinoembryonic antigen measurement, or vandetanib treatment to distinguish between MTC and non-MTC. This approach introduces the potential for misclassification.21,25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“GLP-1 RA use for 1–3 years was associated with increased risk for any thyroid cancer (adjusted HR = 1.58 [CI 1.27–1.95]) and MTC (adjusted HR = 1.78 [CI 1.04–3.05]).25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“In addition, five studies included analyses considering different lag times for outcome assessment, while two studies provided distinct information differentiating between thyroid cancer in general and MTC.25,38,51–53”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“GLP-1 RA use for 1–3 years was associated with increased risk for any thyroid cancer (adjusted HR = 1.58 [CI 1.27–1.95]) and MTC (adjusted HR = 1.78 [CI 1.04–3.05]).25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Of note, there was a large variation in the percentage of cases reported as MTC between the two studies that included this distinction.25,38”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Two studies reported statistically significant findings of increased risk for thyroid cancer in those exposed to GLP-1 RA.25,38”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Of all thyroid cancer cases identified, 15% were MTC, which is higher than expected and might be related to methods used for defining MTC (e.g., testing for calcitonin test/carcinoembryonic antigen or vandetanib treatment).25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Similarly, the potential for residual confounding (e.g., limited evaluation of specific risk factors for thyroid cancer such as obesity, neck radiation, and family history of thyroid cancer) and the role of surveillance bias (e.g., clinicians might be more likely to do a thyroid exam or ultrasound on patients taking GLP-1 RA) are important considerations that have been not thoroughly assessed.25,”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Consistent with previous studies, they also found a signal of disproportionate reporting of GLP-1 RA and overall thyroid cancer and MTC, including 606 reports (mostly from exenatide and liraglutide).25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Recent investigations have highlighted the association between various neoplasms, such as thyroid, breast, and cholangiocarcinoma, and GLP-1 RAs [105-107].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [107]
In the citing paper
“the use of GLP-1 RAs for a duration of 1–3 years was associated with a heightened risk of all thyroid cancers, presenting an adjusted hazard ratio of 1.58 (95% CI 1.27–1.95) and an adjusted HR of 1.78 (95% CI 1.04–3.05), specifically for medullary thyroid cancer.”
In the citing paper
“A case-control study of health insurance data from France indicated an increased risk for thyroid carcinoma with GLP-1RA treatment, with an HR of 1.58 (95% CI 1.27–1.95) (78).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [78]
In the citing paper
“Recent health insurance data from France are indicative of an elevated risk of medullary thyroid carcinoma in individuals treated with GLP-1RAs versus other glucose-lowering agents (35 cases, hazard ratio [HR] 1.78 [95% CI 1.04–3.05]) (78).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [78]
In the citing paper
“in epidemiological studies a significant association with GLP-1RA treatment could be detected for medullary, but not for papillary cancer.12”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“A similar problem affects observational studies; the main survey attempting to discriminate MTC from PTC 12 used indirect markers of limited reliability.21,22”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“which was also confirmed by analyses of serious adverse events reported to the US Food and Drug Administration (FDA) 11,13 and the World Health Organization's pharmacovigilance database Vigi-Base.12,14”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“Some retrospective observational studies detected an increased risk of thyroid cancer in association with GLP-1RA treatment, 11,12”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“This meta-analysis suggests that GLP-1RA treatment may be associated with a moderate increase in risk of thyroid cancer, not dissimilar in its extent from that reported by a recent observational study, 12”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“Also, the use of DPP4-i was found to be associated with a higher risk of thyroid cancer, leading the authors to hypothesize that this association might be partly explained by increased endogenous GLP-1 levels after the inhibition of DPP-4 [132].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [132]
In the citing paper
“The results showed that using GLP-1 RAs increased the risk of both medullary thyroid cancer and thyroid cancer overall, in particular after 1–3 years of treatment exposure (especially for male subjects) [132].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [132]
In the citing paper
“Also, the use of DPP4-i was found to be associated with a higher risk of thyroid cancer, leading the authors to hypothesize that this association might be partly explained by increased endogenous GLP-1 levels after the inhibition of DPP-4 [132].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [132]
Citations
Cites
van Puijenbroek, E., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, T. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,385
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Bezin, J., Duong, M., Lassalle, R., Droz‐Perroteau, C., Pariente, A., Blin, P., & Moore, N. D. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4233 · Cited by 586
Self-citationBiological actions and therapeutic potential of the glucagon-like peptides
Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 509
Essebag, V., Platt, R. W., Abrahamowicz, M., & Pilote, L. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-5 · Cited by 234
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
Asymptotic Theory for Nested Case-Control Sampling in the Cox Regression Model
Goldstein, L. J., & Langholz, B. M. (1992) · The Annals of Statistics · doi:10.1214/aos/1176348895 · Cited by 139
Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
Waser, B., Beetschen, K., Pellegata, N. S., & Reubi, J. C. (2011) · Neuroendocrinology · doi:10.1159/000330447 · Cited by 80
Cited by
Sorted by citations
Items 201–300 of 321
Obesity and GEP-NEN: what’s new?
Boschetti, M., Hasballa, I., Patelli, I., Piras, G., & Albertelli, M. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.12.006 · Cited by 2
Watts, E., Wadsley, J., Sharma, N., Boelaert, K., & The UK Thyroid Cancer Study Group (2025) · Clinical Endocrinology · doi:10.1111/cen.70084 · Cited by 3
Incretin Mimetics in Cancer and Cardiovascular Disease
Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3
Ye, L., Tang, P., Wan, H., Zhong, X., Chen, X., Liu, C., & Huang, R. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s581491 · Cited by 2
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Navigating uncharted waters: long-term implications of GLP-1 agonist use
Sher, T., & Sujka, J. A. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.01.005 · Cited by 2
Os possíveis efeitos adversos dos análogos de GLP-1 em pessoas não-diabéticas e não-obesas
Guerra, L. P. D. C., Antunes, E. M., & da Silva, R. E. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-357 · Cited by 5
Kukova, L., Munir, K. M., Sayeed, A., & Davis, S. N. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2401589 · Cited by 2
Syed, A. A., Britton, J., Assadsangabi, A., Mohammed, N., & Sultan, J. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07717-8 · Cited by 2
Wong, Y. J., & Goh, G. B. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-051 · Cited by 2
Liu, S., Cai, Y., Chen, W., Yuan, X. H., He, Z., & Lin, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1537799 · Cited by 2
Narrative Review of Perioperative Glucagon-like Peptide-1 (GLP-1) Agonists in Spine Surgery
Connelly, J. W., Narayanan, R., Ezeonu, T., Kothari, P., Spina, N., Spiker, W. R., Lawrence, B. D., Brodke, D. S., Schroeder, G. D., & Karamian, B. A. (2025) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001888 · Cited by 2
The effects of incretins as a double-edged sword on cancer
Mavaddat, H., Fouladi, A., Peyrovinasab, A., Khayatan, I., Targhi, H. J., Fakhri, M., Andarzbakhsh, K., Büsselberg, D., Razavi, S. M., & Rezazadeh, A. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11062-5 · Cited by 2
Makunts, T., Joulfayan, H., & Abagyan, R. A. (2023) · medRxiv · doi:10.1101/2023.11.19.23298750 · Cited by 2
Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
Xiao, Y., Meng, J., & Gao, S. (2024) · JAMA · doi:10.1001/jama.2024.2600 · Cited by 2
Li, C., Shen, K., & Pan, L. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01567-y · Cited by 1
Strand, M. W., Chow, D. S., Shen, W., & Watanabe, J. H. (2025) · Pharmacoepidemiology · doi:10.3390/pharma4020009 · Cited by 1
Wong, H. J., Sim, B., Teo, Y. H., Dalakoti, M., & Sia, C. (2025) · Diabetes Care · doi:10.2337/dci25-0023 · Cited by 1
Sen, S., Pai, S., & Harbell, M. W. (2025) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001522 · Cited by 1
Park, H. J., & Lee, S. S. (2025) · Research in Clinical Pharmacy · doi:10.59931/rcp.25.0004 · Cited by 1
Semaglutide and weight management in the Arab countries: Focus on the United Arab Emirates
Semiz, S. (2025) · Health Sciences Review · doi:10.1016/j.hsr.2025.100244 · Cited by 1
Optic disc edema during semaglutide therapy: case report and literature review
Yang, T., Chen, A., Zeng, F., Liu, J., Kamilijiang, Y., Yuan, B., Lu, Y., & Jin, G. (2025) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2025.102476 · Cited by 1
Raghunathan, R. S., Jacobs, A. R., Gajic, Z. Z., Castiglioni, S., Dawood, N. B., Arthurs, L., Ranjbar, S., Rothberger, G. D., Seib, C. D., Prescott, J. D., et al. (2025) · Surgery · doi:10.1016/j.surg.2025.109868 · Cited by 1
Sciscent, B. Y., Eberly, H. W., Lorenz, F. J., Goldrich, D. Y., Goyal, N., & Goldenberg, D. (2026) · OTO Open · doi:10.1002/oto2.70188 · Cited by 2
Harris, M., French, D., Clare, K., Harvie, M., Wilson, D. T., Brown, J., Jayne, D. G., & Renehan, A. G. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03356-7 · Cited by 1
Li, Z., Huang, J., Zhou, S., Luan, Y., Xie, H., Chen, Z., Xu, J., & Qian, J. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/8893769 · Cited by 1
Wu, W., Huang, G.-L., & Cui, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1713815 · Cited by 1
Mixed Medullary and Papillary Thyroid Carcinoma in a Patient on Tirzepatide
Beshay, L. H., Makker, J., & Ahern, S. (2026) · Cureus · doi:10.7759/cureus.107836 · Cited by 1
Hung, C., Yen, F., Huang, J.-Y., & Wei, J. C. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.05.010 · Cited by 1
Kennedy, S., Thomas, J., Darcy, S., Odia, I., Kamdar, D., Pereira, L., Scarola, D., Miles, B., Frank, D. K., Taneja, C., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1834606 · Cited by 1
Anatriello, A., Liguori, V., Pentella, C., Zinzi, A., Longo, M., Caruso, P., Maiorino, M. I., Esposito, K., & Capuano, A. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00864-4 · Cited by 1
Song, K., Zhang, Q., Li, S., Du, Q., Ng, S. K., Chen, Y., Pu, Y., Widjaja, J., Chen, H., & Chen, Y. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00726-3 · Cited by 1
The association between genetically proxied GLP-1 receptor agonists and cancer risks
Zhou, F., Yang, Z., Xing, M., Zong, G., Feng, C., Wang, J., & Geng, X. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005253 · Cited by 1
Hundal, J., Linz, M. O., Anikreddy, S., Sengupta, S., Zhou, K., & Maiti, B. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00061 · Cited by 1
Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer
Muscogiuri, G., Vecchio, G. D., Colangeli, L., Guglielmi, V., Sbraccia, P., & Colao, A. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04458-z · Cited by 1
Xu, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71138 · Cited by 1
Ziegler, D., Kempler, P., Bala, C. G., Mankovsky, B., Schnell, O., Spallone, V., Stirban, A. O., & Tesfaye, S. H. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02241-w · Cited by 2
Deto, Y., Hasegawa, R., Ino, S., Shibata, S., Ohno, K., Itoh, T., Matsumoto, T., & Miki, T. (2026) · Case Reports in Endocrinology · doi:10.1155/crie/9628050 · Cited by 1
Sarma, S., Tran, S., & Fralick, M. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230820 · Cited by 1
Clinical and Surgical Year in Review
Goldner, W. S., & Sinclair, C. F. (2023) · Thyroid · doi:10.1089/thy.2023.0601 · Cited by 1
Pharmakotherapie der Adipositas
Roser, P. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01167-z · Cited by 1
Schilddrüsenkarzinom als potenzielles Risiko bei der Behandlung mit GLP-1-RA?
Rogal, K. (2024) · Info Diabetologie · doi:10.1007/s15034-024-4991-1 · Cited by 1
García‐Vega, D., Cinza‐Sanjurjo, S., Tilves-Bellas, C., Eiras, S., & González‐Juanatey, J. R. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2024.07.004 · Cited by 1
Tsai, Y., Hemphill, N. O., & Kurth, T. (2024) · Diabetologia · doi:10.1007/s00125-024-06300-7 · Cited by 1
Dellinger, A. L., Hughes, L., Griffith, L., Brady, T. E., Ibrahim, A. A., & Goddard, M. K. M. (2024) · Recent Progress in Nutrition · doi:10.21926/rpn.2404018 · Cited by 1
Narrative overview of possible preventive measures for differentiated thyroid carcinomas
de Castro, M. E., Cunha, L. L., & Ward, L. S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41284 · Cited by 1
Kawkgi, O. M. E. (2025) · Clinical Thyroidology · doi:10.1089/ct.2025;37.33-36 · Cited by 1
Endocrinology: What You May Have Missed in 2024
Aman, M., Jeevananthan, A., Martinez-Cruz, M., Namasingh, N., & Batch, B. C. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00990 · Cited by 1
Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies
Vinson, A. J., & Matas, A. J. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000726 · Cited by 1
Zhang, Y., & Li, A. (2025) · Open Medicine · doi:10.1515/med-2025-1184 · Cited by 1
Current and emerging medications for the management of obesity in adults
Inglis, J. M., Kichenadasse, G., & Mangoni, A. A. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.52028 · Cited by 1
Mechano-regulation of GLP-1 production by Piezo1 in intestinal L cellsPreprint
Huang, Y., Mo, H., Yang, J., Gao, L., Tao, T., Shu, Q., Guo, W., Zhao, Y., Lyu, J., Wang, Q., et al. (2024) · eLife · doi:10.7554/elife.97854.1 · Cited by 1
Anderson, B. J., Daele, D. J. V., Claussen, A. D., Tanenbaum, Z. G., & Owen, S. R. (2026) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894261450724 · Cited by 1
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Παππά, Θ. (2023) · Clinical Thyroidology · doi:10.1089/ct.2023;35.18-20
Halimi, S. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.03.008
Tveito, K. (2023) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.23.0304
Schirmer, M., Brandt, S., Zorn, S., & Wabitsch, M. (2023) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2079-9133
Glucagon-like peptide-1 receptor agonists : A new step towards weight management
Omar, M. (2023) · American Journal of Medical and Clinical Research & Reviews · doi:10.58372/2835-6276.1073
Schattenseiten der Adipositas-Blockbuster beleuchtet
Chakaroun, R. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01106-4
The emerging role of GLP-1 analogs in weight control
Filho, S. S., Comby, I., Garcez, L. R., Moreira, T. A., Braga, T. D. O., Miranda, S. C. D., Silva, G. A. B. E., & Quartezani, T. E. E. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n1-426
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Disorders
Kesavadev, J., KOVIL, R. R., Basu, D., Chaudhuri, S. R., & Bhartia, M. (2022) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_2_23
Pas de risque thyroïdien avec les agonistes du GLP-1
Dalmat, Y.-M. (2024) · Option/Bio · doi:10.1016/s0992-5945(24)00036-9
Nouveaux traitements contre l’obésité
Sarma, S., Tran, S., & Fralick, M. (2024) · Canadian Medical Association Journal · doi:10.1503/cmaj.230820-f
Nuevos fármacos para la obesidad (con y sin diabetes)
Llover, M. N., & Jiménez, M. C. (2024) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2024.01.001
Dong, J., Starkey, T., Cheng, V. W. T., Clark, J., Pinato, D. J., Robinson, T., Tilby, M., Turnbull, C. D., & Lee, L. Y. W. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4865052
Medikamentöse Adipositastherapie bei Typ-2-Diabetes
Kantowski, T., Wiesch, C. S. Z., Aberle, J., & Lautenbach, A. (2024) · CME · doi:10.1007/s11298-024-3862-3
García‐Vega, D., Cinza‐Sanjurjo, S., Tilves-Bellas, C., Eirás, S., & González‐Juanatey, J. R. (2024) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2024.07.003 · Cited by 1
Erhöhen GLP-1-Rezeptoragonisten das Risiko für Schilddrüsenkarzinome?
Rogal, K. (2024) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-024-0734-7
Research Progress on the Mechanism and Clinical Characteristics of Obesity in Thyroid Cancer
吴, 梦. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14113029
Wann ist „Schluss mit lustig“? – gynäkologische Sicht
Neulen, J. (2024) · Die Gynäkologie · doi:10.1007/s00129-024-05306-x
Semaglutide: de la moda a la evidencia científica. A propósito de una Revisión Narrativa
Bueno, E., Jara-Ruiz, E., Jara, J., Arce, M., Ramírez, A. I., & Canata, G. (2024) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2024.057.03.102 · Cited by 2
Role of Incretin Mimetics in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_4
McGuigan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01154-4
GLP-1 agonists for type 2 diabetes mellitus and heart failure
Preijers, T., & Lafeber, M. (2024) · Geneesmiddelenbulletin · doi:10.35351/gebu.2024.10.14
Glucagon-like Peptide-1 Receptor Agonists and Thyroid Cancer: Myth or Reality?
Goldenberg, R. (2025) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2025.3137
Antidiabetic agents as potential cytotoxic candidates for cancer therapy
Alnaser, R. I., Alassaf, F. A., & Abed, M. N. (2024) · Forum of Clinical Oncology · doi:10.2478/fco-2023-0041 · Cited by 1
Gewichtsreduktion mit Inkretinmimetika – Chancen und Risiken
Zech, T., Kirchweger, B., & Fürst, R. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01918-0
Adipositas und Herz: neue Medikamente und neue Strategien für Kardiologen
Hollstein, T. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2606-7020
The physiologic and psychologic effects of glucagon-like peptide-1 receptor agonists
Bradwisch, S. A., Smith, E. M., Wilson-Mooney, C., & Donahue-Stathis, C. (2025) · Nursing · doi:10.1097/nsg.0000000000000223
Dobrowolska, J., Kozak, K., Morawa, A., Peisert, L., Wdowiak, K., & Chudek, J. T. (2025) · Annales Academiae Medicae Silesiensis · doi:10.18794/aams/207726
Jaradat, J. H., Alahmad, R., Jaghbeer, M. A., Abdelaziz, A. A., Afifeh, N. A., Afifeh, G. A., Rao, A., Alzoubi, A., & Nashwan, A. J. (2025) · Cureus · doi:10.7759/cureus.96071 · Cited by 1
GLP-1-RA und Schilddrüsenkrebs: Gibt es einen Zusammenhang?
Müssig, K. (2025) · Info Diabetologie · doi:10.1007/s15034-025-5201-5
Zhou, J., Zheng, Y., Xu, B., Long, S., Zhu, L.-E., Liu, Y., Li, C., Zhang, Y., Liu, M., & Wu, X. (2024) · Figshare · doi:10.6084/m9.figshare.26680684
Khawandanah, D. O., Alyamani, F. F., Almutairi, B. R., Almutairi, B. A., Alharbi, R. M., Alghanmi, S., Alsouri, M. T., & ALMUTAIRI, A. R. (2025) · Saudi Journal of Clinical Pharmacy · doi:10.4103/sjcp.sjcp_22_25
OBESITY AS A MODIFIABLE DETERMINANT OF THYROID DYSFUNCTION, STRUCTURAL CHANGES, AND THYROID CANCER
Baran, K., Grygorowicz, A., Ględa, M., Szyszka, M., Radecka, W., Kozak, W., Szreiber, A., Grela, K., Nowacka, K., Jabłoński, K., et al. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4647
Khela, H. S., Kishan, A., Manriquez, A. H., Kirby, L., Chisango, Z. M., Carayannopoulos, N. L., Singh, M., Cottrill, E. J., Avedian, R. S., Kleck, C. J., et al. (2026) · Spine Open · doi:10.1097/bn9.0000000000000051
Deng, C.-X., Chen, Z.-M., Tang, Y.-X., Xi, Z.-X., Wang, S.-Y., Wu, H.-Y., Xu, B., & Xu, T.-C. (2026) · World Journal of Pharmacology · doi:10.5497/wjp.v15.i1.113080
ADVERSE EFFECTS OF GLP-1 RECEPTOR AGONISTS: A COMPREHENSIVE APPROACH
Sapeda, N., Lusarczyk, W., Truszyńska-Zawisza, A., Gorczyca, K., Młocek, A., Romanowska, Z., & Białas, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4111
Mechanisms in diabetes mellitus: Relationships to metabolism and/or neoplasia
D’Elia, J. A., Roshan, B., & Weinrauch, L. A. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109289
Inkretinmimetika und Schilddrüsenkrebs: Gibt es ein Risiko?
Parzer, V. (2026) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-026-00297-7
Eisa, N., & Barood, O. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.03.003
Lai, J. C. (2026) · GRURRR. Gewerblicher Rechtsschutz und Urheberrecht, Rechtsprechungs-Report/GRUR-DVD/GRUR-CD/IIC/Gewerblicher Rechtsschutz und Urheberrecht/Gewerblicher Rechtsschutz und Urheberrecht. Internationaler Teil · doi:10.1007/s40319-026-01692-y
Current trends in pharmacotherapy of overweight and obesity
Ürgeová, A., & Kozárová, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.099
Luongo, C., & Triggiani, R. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01789-z
Glucagon-like peptide-1 receptor agonists & thyroid cancer: What thyroid surgeons should know
Yuan, L., & Wiseman, S. M. (2026) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2026.116975
Safety of glucagon-like peptide-1 agonists: data from the Russian National pharmacovigilance system
Gomon, Y. М., Александровна, М. Е., Колбин, А. С., & Витальевич, Г. К. (2026) · Real-World Data & Evidence · doi:10.37489/2782-3784-myrwd-092
Мамедов, М. Н., Друк, И. В., & Akhundova, H. R. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-6812
Lin, C., Chen, W., Liu, S. X., Cao, B., Ge, Y., Li, Y., Liu, Y., Guo, T., Xu, J., & Wang, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-115236
Fouad, Y. M., Abdelghany, W. A., & Sheemy, R. Y. E. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i5.118303
Metadata
- Authors
- Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L.
- Affiliations
- Université de Bordeaux (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- 4Département de Pharmacologie Médicale et Toxicologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
- Inserm (FR)
- Corresponding author
- Faillie, Jean-Luc
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-11-10
- Volume
- 46
- Issue
- 2
- Pages
- 384-390
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4308701204
- Cited by
- 320
- References
- 17
- Citations by year
- 2026: 64 · 2025: 118 · 2024: 94 · 2023: 42 · 2022: 2
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Funders
- Agence Nationale de Sécurité du Médicament et des Produits de Santé (2019S015)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- GLP-1 receptor agonists, thyroid cancer, medullary thyroid carcinoma, type 2 diabetes, drug safety, cancer risk, treatment duration
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Thyroid Neoplasms, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
